Zimmer Biomet Holdings, Inc.
ZBHHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Zimmer Biomet Holdings, Inc. (ZBH) is listed under Medical Devices. Valued at $17.97B, ZBH is a large-cap name in its sector. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
Market Cap
$17.97B
Beta
0.47
P/E (TTM)
22.87
P/E (Fwd)
10.39
EPS (TTM)
$4.12
EPS (Fwd)
$9.07
ROE
6.4%
ROA
4.0%
Cash
$464.5M
Total Debt
$7.60B
Free CF
$1.09B
52W Change
-4.1%
Annual Financials
Cash vs Debt
Where ZBH stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, ZBH finished 9.61% above its 150-day moving average ($90.76) and 9.66% above its 200-day moving average ($90.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZBH overbought or oversold?
At the August 28, 2026 close, ZBH's RSI(14) was 58.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $464.5M in cash, though total debt stands at $7.60B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $1.09B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 6.4%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $6.94B to $8.23B.
ZBH's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Zimmer Biomet Holdings, Inc. and its sector.